一线[18F]F-胆碱PET/CT用于原发性甲状旁腺功能亢进症的cost-effectiveness研究:APACH2随机诊断试验
基于APACH2随机对照试验的cost-effectiveness分析,纳入57例原发性甲状旁腺功能亢进症患者,比较一线[18F]F-胆碱PET/CT与[99mTc]Tc-sestaMIBI SPECT/CT引导微创甲状旁腺切除术的成本效果。结果显示FCH1策略平均费用增加€136.5(p=0.53),但有效率为85% vs 56%(p=0.037),ICER为€471/额外治愈1例。结论认为FCH1策略以极小额外成本使更多患者直接接受成功的门诊MIP。
要点
- 一线FCH PET/CT较MIBI SPECT/CT提高有效MIP转诊率29%(85% vs 56%,p=0.037)。
- FCH1策略平均费用较MIBI1增加€136.5(p=0.53),ICER为€471/额外治愈1例。
- 概率敏感性分析支持FCH1策略略贵但更有效的结论稳健。
核心结论
- 一线FCH PET/CT用于pHPT手术管理,可使更多患者直接接受成功的门诊MIP,从医保支付方角度仅增加极小额外成本。
研究设计与样本
- 基于随机对照多中心APACH2试验的cost-effectiveness分析,纳入57例pHPT患者,随机分为FCH1组(n=29)和MIBI1组(n=28)。
- 从支付方角度整合随机化后至6个月内的直接医院成本,计算增量成本效果比(ICER),并进行确定性和概率敏感性分析。
主要发现
- FCH1组平均费用€3,843.5(95%CI: 3442.5-4244.5),MIBI1组€3,707.0(95%CI: 3606.9-3807.6),差值€136.5(p=0.53)。
- FCH1组平均有效率85%(95%CI: 0.71-0.99),MIBI1组56%(95%CI: 0.36-0.76),差值29%(p=0.037)。
- FCH1相比MIBI1的ICER为€471/额外治愈1例;确定性敏感性分析ICER范围€-567至€1,507。
关键数值与推荐
- 有效性标准为真阳性一线影像引导MIP后1个月血钙正常率。
临床怎么用
- 在pHPT手术管理中,一线FCH PET/CT可替代MIBI SPECT/CT,以少量额外成本提高成功MIP转诊率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The randomized controlled multicentre APACH2 trial showed that first-line [18F]F-choline (FCH1) PET/CT is superior to [99mTc]Tc-sestaMIBI (MIBI1) SPECT/CT for referring patients with primary hyperparathyroidism (pHPT) to effective minimally invasive parathyroidectomy (MIP). The aim of this study was to weigh this clinical gain against the increase in imaging costs. METHODS: The effectiveness criterion per imaging strategy was the rate of normocalcemia at one month post true-positive first-line imaging-guided MIP. The medico-economic analysis, carried out from the payer's perspective, integrated direct hospital costs up to 6 months after randomization. The result of the cost-effectiveness analysis was calculated in the form of an incremental cost-effectiveness ratio (ICER), establishing the average cost necessary to cure an additional person by switching from the usual MIBI1 strategy to the new FCH1 strategy. Sensitivity analyses were used to test the robustness of the ICER. RESULTS: The APACH2 trial enrolled 57 patients from November 2019 to May 2022 in four centres, randomized between FCH1 (n = 29) or MIBI1 (n = 28). The differential cost between FCH1 and MIBI1 strategies was €136.5 (average cost FCH1 €3,843.5 (95% CI: 3442.5-4244.5) vs MIBI1 €3,707.0 (95% CI: 3606.9- 3807.6), p = 0.53), with a differential effectiveness of 29% (average effectiveness FCH1 85% (95% CI: 0.71-0.99) vs MIBI1 56% (95% CI: 0.36-0.76), p = 0.037). The ICER of FCH1 compared to MIBI1 was €471 for referring one additional patient to MIP followed by normocalcemia. Deterministic sensitivity analysis showed ICER to vary from €-567 to €1,507. The probabilistic sensitivity analysis showed the robustness of our finding that the FCH1 strategy is slightly more expensive but also more effective than the MIBI1 strategy. CONCLUSION: First-line FCH PET/CT in the surgical management of pHPT allows more patients to be referred directly to successful outpatient MIP at a minimal additional cost from a health insurance point of view.
引用
- Quak E, Lasne-Cardon A, Cavarec M, et al. First-line [18F]F-choline PET/CT in primary hyperparathyroidism: a cost-effectiveness study from the diagnostic randomized APACH2 trial. Eur J Nucl Med Mol Imaging. 2026. PMID: 41491031. doi:10.1007/s00259-025-07728-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。